Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.
出版信息
Paediatr Child Health. 1999 Oct;4(7):474-89.
Abstract
摘要
相似文献
1
2
3
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.帕利珠单抗和呼吸道合胞病毒免疫球蛋白静脉注射剂预防呼吸道合胞病毒感染的修订使用指征。
Pediatrics. 2003 Dec;112(6 Pt 1):1447-52. doi: 10.1542/peds.112.6.1447.
4
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.高危严重呼吸道合胞病毒感染婴儿接受帕利珠单抗预防的死亡率和发病率：系统文献回顾和荟萃分析。
Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990.
5
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.呼吸道合胞病毒预防在早产儿中的成本效益
Pediatrics. 1999 Sep;104(3 Pt 1):419-27. doi: 10.1542/peds.104.3.419.
6
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.呼吸道合胞病毒感染的预防：帕利珠单抗的使用指征及呼吸道合胞病毒免疫球蛋白静脉注射剂使用的最新情况。美国儿科学会传染病委员会及胎儿与新生儿委员会
Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211.
7
Palivizumab in the prophylaxis of respiratory syncytial virus infection.帕利珠单抗预防呼吸道合胞病毒感染
Expert Rev Anti Infect Ther. 2005 Oct;3(5):719-26. doi: 10.1586/14787210.3.5.719.
8
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2014 May 22(5):CD007743. doi: 10.1002/14651858.CD007743.pub5.
9
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗预防囊性纤维化儿童呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007743. doi: 10.1002/14651858.CD007743.pub3.
10
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2013 Jun 5(6):CD007743. doi: 10.1002/14651858.CD007743.pub4.
引用本文的文献
1
Clinical research on RSV prevention in children and pregnant women: progress and perspectives.儿童和孕妇呼吸道合胞病毒预防的临床研究：进展与展望。
Front Immunol. 2024 Jan 24;14:1329426. doi: 10.3389/fimmu.2023.1329426. eCollection 2023.
2
The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories.帕利珠单抗的拼凑情况：加拿大各省和地区呼吸道合胞病毒预防指南的差异
Paediatr Child Health. 2020 Feb 20;26(2):e115-e120. doi: 10.1093/pch/pxz166. eCollection 2021 Apr-May.
3
Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.帕利珠单抗的真实世界疗效：加拿大安大略省 1993-2017 年的基于人群研究。
Arch Dis Child. 2021 Feb;106(2):173-179. doi: 10.1136/archdischild-2020-319472. Epub 2020 Aug 28.
4
Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.呼吸道合胞病毒（RSV）感染的成人造血细胞移植（HCT）受者对融合蛋白中弗林蛋白酶可切割的27个氨基酸肽（p27）的抗体反应。
Vaccines (Basel). 2020 Apr 21;8(2):192. doi: 10.3390/vaccines8020192.
5
Preventing hospitalizations for respiratory syncytial virus infection.预防呼吸道合胞病毒感染导致的住院治疗。
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321.
6
Respiratory syncytial virus infections in infants affected by primary immunodeficiency.婴儿原发性免疫缺陷患者的呼吸道合胞病毒感染。
J Immunol Res. 2014;2014:850831. doi: 10.1155/2014/850831. Epub 2014 Jun 25.
7
The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.帕利珠单抗对降低努纳武特地区婴儿因呼吸道合胞病毒导致的住院率的实际效果。
Can Respir J. 2014 May-Jun;21(3):185-9. doi: 10.1155/2014/941367. Epub 2013 Dec 23.
8
A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.基于细胞的高通量筛选方法用于发现新的呼吸道合胞病毒抑制剂。
Virol J. 2013 Jan 10;10:19. doi: 10.1186/1743-422X-10-19.
9
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.特殊人群中的呼吸道住院和呼吸道合胞病毒预防。
Eur J Pediatr. 2012 May;171(5):833-41. doi: 10.1007/s00431-011-1654-8. Epub 2011 Dec 28.
10
Prevention of respiratory syncytial virus infection.呼吸道合胞病毒感染的预防
Paediatr Child Health. 2009 Oct;14(8):521-32. doi: 10.1093/pch/14.8.521.
本文引用的文献
1
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?健康早产婴儿中的严重呼吸道合胞病毒感染：我们试图预防什么？
Paediatr Child Health. 1998 Nov;3(6):402-4. doi: 10.1093/pch/3.6.402.
2
Respiratory syncytial virus immune globulin intravenous.呼吸道合胞病毒免疫球蛋白静脉注射剂
Paediatr Child Health. 1998 Jan;3(1):11-4. doi: 10.1093/pch/3.1.11.
3
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.使用帕利珠单抗（一种人源化呼吸道合胞病毒单克隆抗体）进行免疫预防以预防高危婴儿呼吸道合胞病毒感染：共识意见。
Pediatr Infect Dis J. 1999 Mar;18(3):223-31. doi: 10.1097/00006454-199903000-00004.
4
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.通过使用针对呼吸道合胞病毒F蛋白的人源化单克隆抗体减少插管婴儿气管吸出物中的呼吸道合胞病毒（RSV）
J Infect Dis. 1998 Dec;178(6):1555-61. doi: 10.1086/314523.
5
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.呼吸道合胞病毒感染的预防：帕利珠单抗的使用指征及呼吸道合胞病毒免疫球蛋白静脉注射剂使用的最新情况。美国儿科学会传染病委员会及胎儿与新生儿委员会
Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211.
6
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.呼吸道合胞病毒免疫球蛋白用于预防先天性心脏病婴幼儿和儿童的呼吸道合胞病毒疾病。心脏研究组。
J Pediatr. 1998 Oct;133(4):492-9. doi: 10.1016/s0022-3476(98)70056-3.
7
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.呼吸道合胞病毒人源化单克隆抗体在早产儿和支气管肺发育不良婴儿中的安全性和药代动力学。MEDI - 493研究组
Pediatr Infect Dis J. 1998 Sep;17(9):787-91. doi: 10.1097/00006454-199809000-00007.
8
9
Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.呼吸道合胞病毒免疫球蛋白预防极低出生体重儿下呼吸道疾病住院的成本与效益
Pediatr Infect Dis J. 1998 Jul;17(7):587-93. doi: 10.1097/00006454-199807000-00003.
10
A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.一项关于使用呼吸道合胞病毒免疫球蛋白预防住院治疗的需治疗人数分析。
Arch Pediatr Adolesc Med. 1998 Apr;152(4):358-66. doi: 10.1001/archpedi.152.4.358.
Zotero 插件